Carbamylation of proteins through reactive cyanate has been demonstrated to predict an increased cardiovascular risk. Cyanate is formed in vivo by breakdown of urea and at sites of inflammation by the phagocyte protein myeloperoxidase. Because myeloperoxidase (MPO) associates with high-density lipoprotein (HDL) in human atherosclerotic intima, we examined in the present study whether cyanate specifically targets HDL. Mass spectrometry analysis revealed that protein carbamylation is a major posttranslational modification of HDL. The carbamyllysine content of lesion-derived HDL was more than 20-fold higher in comparison with 3-chlorotyrosine levels, a specific oxidation product of MPO. Notably, the carbamyllysine content of lesion-derived HDL was five- to eightfold higher when compared with lesion-derived low-density lipoprotein (LDL) or total lesion protein and increased with lesion severity. The carbamyllysine content of HDL, but not of LDL, correlated with levels of 3-chlorotyrosine, suggesting that MPO mediated carbamylation in the vessel wall. Remarkably, one carbamyllysine residue per HDL-associated apolipoprotein A-I was sufficient to induce cholesterol accumulation and lipid-droplet formation in macrophages through a pathway requiring the HDL-receptor scavenger receptor class B, type I. The present results raise the possibility that HDL carbamylation contributes to foam cell formation in atherosclerotic lesions. Antioxid. Redox Signal. 14, 2337–2346.
Get full access to this article
View all access options for this article.
References
1.
ApostolovEO, RayD, SavenkaAV, ShahSV, BasnakianAG. Chronic uremia stimulates LDL carbamylation and atherosclerosis. J Am Soc Nephrol, 21:1852–1857. 2010.
2.
ApostolovEO, ShahSV, OkE, BasnakianAG. Quantification of carbamylated LDL in human sera by a new sandwich ELISA. Clin Chem, 51:719–728. 2005.
BergtC, PennathurS, FuX, ByunJ, O'BrienK, McDonaldTO, SinghP, AnantharamaiahGM, ChaitA, BrunzellJ, GearyRL, OramJF, HeineckeJW. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A, 101:13032–13037. 2004.
5.
ChinettiG, GbaguidiFG, GriglioS, MallatZ, AntonucciM, PoulainP, ChapmanJ, FruchartJC, TedguiA, Najib-FruchartJ, StaelsB. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation, 101:2411–2417. 2000.
6.
DammM, HolzerM, RadspielerG, MarscheG, KappeCO. Microwave-assisted high-throughput acid hydrolysis in silicon carbide microtiter platforms: a rapid and low volume sample preparation technique for total amino acid analysis in proteins and peptides. J Chromatogr A, 35:363–379. 2010.
7.
DuaS, MacleanMJ, FitzgeraldM, McAnoyAM, BowieJH. Is the hypothiocyanite anion (OSCN)- the major product in the peroxidase catalyzed oxidation of the thiocyanate anion (SCN)-? A joint experimental and theoretical study. J Phys Chem A, 110:4930–4936. 2006.
8.
FournierN, PaulJL, AtgerV, CognyA, SoniT, Llera-MoyaM, RothblatG, MoattiN. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler Thromb Vasc Biol, 17:2685–2691. 1997.
9.
HazenSL, CrowleyJR, MuellerDM, HeineckeJW. Mass spectrometric quantification of 3-chlorotyrosine in human tissues with attomole sensitivity: a sensitive and specific marker for myeloperoxidase-catalyzed chlorination at sites of inflammation. Free Radic Biol Med, 23:909–916. 1997.
10.
HiranoK, YamashitaS, NakagawaY, OhyaT, MatsuuraF, TsukamotoK, OkamotoY, MatsuyamaA, MatsumotoK, MiyagawaJ, MatsuzawaY. Expression of human scavenger receptor class B type I in cultured human monocyte-derived macrophages and atherosclerotic lesions. Circ Res, 85:108–116. 1999.
11.
KlebanoffSJ. Myeloperoxidase: friend and foe. J Leukoc Biol, 77:598–625. 2005.
12.
KrausLM, ElbergerAJ, HandorfCR, PabstMJ, KrausAPJr. Urea-derived cyanate forms epsilon-amino-carbamoyl-lysine (homocitrulline) in leukocyte proteins in patients with end-stage renal disease on peritoneal dialysis. J Lab Clin Med, 123:882–891. 1994.
13.
KriegerM. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest, 108:793–797. 2001.
14.
LarredeS, QuinnCM, JessupW, FrisdalE, OlivierM, HsiehV, KimMJ, VanEM, CouvertP, CarrieA, GiralP, ChapmanMJ, GuerinM, LeGW. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler Thromb Vasc Biol, 29:1930–1936. 2009.
15.
LiuT, KriegerM, KanHY, ZannisVI. The effects of mutations in helices 4 and 6 of ApoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for efficient lipid transport. J Biol Chem, 277:21576–21584. 2002.
16.
MarscheG, FrankS, HrzenjakA, HolzerM, DirnbergerS, WadsackC, ScharnaglH, StojakovicT, HeinemannA, OettlK. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ Res, 104:750–757. 2009.
17.
MarscheG, FrankS, RaynesJG, KozarskyKF, SattlerW, MalleE. The lipidation status of acute-phase protein serum amyloid A determines cholesterol mobilization via scavenger receptor class B, type I. Biochem J, 402:117–124. 2007.
18.
MarscheG, FurtmullerPG, ObingerC, SattlerW, MalleE. Hypochlorite-modified high-density lipoprotein acts as a sink for myeloperoxidase in vitro. Cardiovasc Res, 79:187–194. 2008.
19.
MarscheG, HammerA, OskolkovaO, KozarskyKF, SattlerW, MalleE. Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. J Biol Chem, 277:32172–32179. 2002.
20.
MarscheG, Levak-FrankS, QuehenbergerO, HellerR, SattlerW, MalleE. Identification of the human analog of SR-BI and LOX-1 as receptors for hypochlorite-modified high density lipoprotein on human umbilical venous endothelial cells. FASEB J, 15:1095–1097. 2001.
21.
MarscheG, ZimmermannR, HoriuchiS, TandonNN, SattlerW, MalleE. Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein. J Biol Chem, 278:47562–47570. 2003.
22.
MatyashV, LiebischG, KurzchaliaTV, ShevchenkoA, SchwudkeD. Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J Lipid Res, 49:1137–1146. 2008.
23.
MatzCE, JonasA. Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J Biol Chem, 257:4535–4540. 1982.
24.
MineoC, ShaulPW. Role of high-density lipoprotein and scavenger receptor B type I in the promotion of endothelial repair. Trends Cardiovasc Med, 17:156–161. 2007.
25.
MuraoK, TerpstraV, GreenSR, KondratenkoN, SteinbergD, QuehenbergerO. Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes. J Biol Chem, 272:17551–17557. 1997.
26.
NavabM, ReddyST, Van LentenBJ, AnantharamaiahGM, FogelmanAM. The role of dysfunctional HDL in atherosclerosis. J Lipid Res, 50,suppl:S145–S149. 2009.
27.
OimomiM, NishimotoS, MatsumotoS, HatanakaH, IshikawaK, KawasakiT, YoshimuraY, BabaS. Carbamylated plasma protein in renal failure. Nippon Jinzo Gakkai Shi, 28:269–271. 1986.
28.
PapahadjopoulosD, WeissL. Amino groups at the surfaces of phospholipid vesicles. Biochim Biophys Acta, 183:417–426. 1969.
29.
ShaoB, PennathurS, PaganiI, OdaMN, WitztumJL, OramJF, HeineckeJW. Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J Biol Chem, 285:18473–18484. 2010.
30.
StaryHC, ChandlerAB, DinsmoreRE, FusterV, GlagovS, InsullWJr, RosenfeldME, SchwartzCJ, WagnerWD, WisslerRW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation, 92:1355–1374. 1995.
31.
StockerR, KeaneyJFJr. Role of oxidative modifications in atherosclerosis. Physiol Rev, 84:1381–1478. 2004.
32.
SvenssonPA, EnglundMC, SnackestrandMS, HaggDA, OhlssonBG, StemmeV, Mattsson-HultenL, ThelleDS, FagerbergB, WiklundO, CarlssonLM, CarlssonB. Regulation and splicing of scavenger receptor class B type I in human macrophages and atherosclerotic plaques. BMC Cardiovasc Disord, 5:25. 2005.
33.
UchidaK. Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med, 28:1685–1696. 2000.
34.
van DalenCJ, WhitehouseMW, WinterbournCC, KettleAJ. Thiocyanate and chloride as competing substrates for myeloperoxidase. Biochem J, 327:487–492. 1997.
35.
VanEM, BosIS, HildebrandRB, Van RijBT, Van BerkelTJ. Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. Am J Pathol, 165:785–794. 2004.
ZhengL, NukunaB, BrennanML, SunM, GoormasticM, SettleM, SchmittD, FuX, ThomsonL, FoxPL, IschiropoulosH, SmithJD, KinterM, HazenSL. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest, 114:529–541. 2004.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
